AlAnazi FH, Al-kuraishy HM, Alexiou A et al (2023) Primary hypothyroidism and Alzheimer’s disease: a tale of two. Cell Mol Neurobiol 43:3405–3416. https://doi.org/10.1007/s10571-023-01392-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ali NH, Al-kuraishy HM, Al-Gareeb AI et al (2023) The probable role of tissue plasminogen activator/neuroserpin axis in Alzheimer’s disease: a new perspective. Acta Neurol Belg. https://doi.org/10.1007/s13760-023-02403-x

Article  PubMed  PubMed Central  Google Scholar 

Ali NH, Al-Kuraishy HM, Al-Gareeb AI et al (2024) Neprilysin inhibitors and risk of Alzheimer’s disease: a future perspective. J Cell Mol Med. https://doi.org/10.1111/jcmm.17993

Article  PubMed  PubMed Central  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Alsayegh AA et al (2023) Insights on benzodiazepines’ potential in Alzheimer’s disease. Life Sci 320:121532. https://doi.org/10.1016/j.lfs.2023.121532

Article  CAS  PubMed  Google Scholar 

Al-Kuraishy HM, Jabir MS, Al-Gareeb AI et al (2023d) Evaluation and targeting of amyloid precursor protein (APP)/amyloid beta (Aβ) axis in amyloidogenic and non-amyloidogenic pathways: a time outside the tunnel. Ageing Res Rev 92:102119. https://doi.org/10.1016/j.arr.2023.102119

Article  CAS  PubMed  Google Scholar 

Al-kuraishy HM, Jabir MS, Albuhadily AK et al (2023a) The link between metabolic syndrome and Alzheimer disease: a mutual relationship and long rigorous investigation. Ageing Res Rev 91:102084. https://doi.org/10.1016/j.arr.2023.102084

Article  PubMed  Google Scholar 

Al-kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE-S (2023b) Benzodiazepines in Alzheimer’s disease: beneficial or detrimental effects. Inflammopharmacology 31:221–230. https://doi.org/10.1007/s10787-022-01099-4

Article  CAS  PubMed  Google Scholar 

Al-kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE-S (2023c) Long-term use of metformin and Alzheimer’s disease: beneficial or detrimental effects. Inflammopharmacology 31:1107–1115. https://doi.org/10.1007/s10787-023-01163-7

Article  CAS  PubMed  Google Scholar 

Alrouji M, Al-Kuraishy HM, Al-Gareeb AI et al (2023) The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer’s diseases. Diabetol Metab Syndr 15:101. https://doi.org/10.1186/s13098-023-01082-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alsubaie N, Al-kuraishy HM, Al-Gareeb AI et al (2022) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12:1290. https://doi.org/10.3390/brainsci12101290

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arad E, Yosefi G, Kolusheva S, Bitton R, Rapaport H, Jelinek R (2022) Native glucagon amyloids catalyze key metabolic reactions. ACS Nano 16(8):12889–12899

Article  CAS  PubMed  Google Scholar 

Balmik AA, Das R, Sonawane SK, Chinnathambi S (2022) Aggregation species of amyloid-β and Tau oligomers in Alzheimer’s disease: role in therapeutics and diagnostics. In: Alzheimer’s Disease. Royal Society of Chemistry, Cambridge, pp 137–169

Behl C (2023) The psychiatrist and pathologist aloysius alzheimer and his seminal findings. Alzheimer’s disease research. Springer, Cham, pp 27–45

Chapter  Google Scholar 

Bi Z, Wang L, Wang W (2023) Evaluating the effects of glucagon-like peptide-1 receptor agonists on cognitive function in Alzheimer’s disease: a systematic review and meta-analysis. Adv Clin Exp Med 32(11):1223–1231

Article  PubMed  Google Scholar 

Biessels GJ (2009) Hypoglycemia and dementia in type 2 diabetes: chick or egg? Nat Rev Endocrinol 5:532–534. https://doi.org/10.1038/nrendo.2009.182

Article  CAS  PubMed  Google Scholar 

Bree AJ, Puente EC, Daphna-Iken D, Fisher SJ (2009) Diabetes increases brain damage caused by severe hypoglycemia. Am J Physiol Metab 297:194–201. https://doi.org/10.1152/ajpendo.91041.2008

Article  CAS  Google Scholar 

Cai Y, Liu J, Wang B et al (2022) Microglia in the neuroinflammatory pathogenesis of Alzheimer’s disease and related therapeutic targets. Front Immunol. https://doi.org/10.3389/fimmu.2022.856376

Article  PubMed  PubMed Central  Google Scholar 

Calabrò M, Rinaldi C, Santoro G, Crisafulli C (2021) The biological pathways of Alzheimer disease: a review. AIMS Neurosci 8:86–132. https://doi.org/10.3934/Neuroscience.2021005

Article  PubMed  Google Scholar 

Canepa E, Domenicotti C, Marengo B et al (2013) Cyclic adenosine monophosphate as an endogenous modulator of the amyloid-β precursor protein metabolism. IUBMB Life 65:127–133. https://doi.org/10.1002/iub.1109

Article  CAS  PubMed  Google Scholar 

Cao Q, Tan C-C, Xu W et al (2020) The prevalence of dementia: a systematic review and meta-analysis. J Alzheimer’s Dis 73:1157–1166. https://doi.org/10.3233/JAD-191092

Article  Google Scholar 

Chakrabarty R, Yousuf S, Singh MP (2022) Contributive role of hyperglycemia and hypoglycemia towards the development of Alzheimer’s disease. Mol Neurobiol 59:4274–4291. https://doi.org/10.1007/s12035-022-02846-y

Article  CAS  PubMed  Google Scholar 

Chan O, Cheng H, Herzog R, Czyzyk D, Zhu W, Wang A, McCrimmon RJ, Seashore MR, Sherwin RS (2008) Increased GABAergic tone in the ventromedial hypothalamus contributes to suppression of counterregulatory responses after antecedent hypoglycemia. Diabetes 57:1363–1370

Article  CAS  PubMed  Google Scholar 

Chávez-Gutiérrez L, Szaruga M (2020) Mechanisms of neurodegeneration—insights from familial Alzheimer’s disease. Seminars in cell & developmental biology, vol 105. Academic Press, Washington, DC, pp 75–85

Google Scholar 

Chen Y, Liu Z, Yu Y et al (2017) Effect of recurrent severe hypoglycemia on cognitive performance in adult patients with diabetes: a meta-analysis. Curr Med Sci 37:642–648. https://doi.org/10.1007/s11596-017-1784-y

Article  Google Scholar 

Chen S, Chen S-T, Sun Y et al (2019) Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer’s disease. Redox Biol 22:101133. https://doi.org/10.1016/j.redox.2019.101133

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cuestas Torres DM, Cardenas FP (2020) Synaptic plasticity in Alzheimer’s disease and healthy aging. Rev Neurosci 31:245–268. https://doi.org/10.1515/revneuro-2019-0058

Article  PubMed  Google Scholar 

Dewanjee S, Chakraborty P, Bhattacharya H et al (2022) Altered glucose metabolism in Alzheimer’s disease: role of mitochondrial dysfunction and oxidative stress. Free Radic Biol Med 193:134–157. https://doi.org/10.1016/j.freeradbiomed.2022.09.032

Article  CAS  PubMed  Google Scholar 

Dudley A, Khalil MI, Mullins G et al (2022) Hypoglycaemic events resembling focal seizures—a case report and literature review. Seizure 94:10–17. https://doi.org/10.1016/j.seizure.2021.11.002

Article  PubMed  Google Scholar 

Dybjer E, Engström G, Helmer C et al (2020) Incretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a population-based study. Diabetes Med 37:1157–1166. https://doi.org/10.1111/dme.14267

Article  CAS  Google Scholar 

Ferreira ST (2021) Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer’s disease. J Neuroendocrinol. https://doi.org/10.1111/jne.12959

Article  PubMed  Google Scholar 

Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27–36. https://doi.org/10.1038/nm.3761

Article  CAS  PubMed  Google Scholar